ANAlaa-Eldin F. Nassar

Alaa-Eldin F. Nassar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alaa-Eldin F. Nassar has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Characterization of Short-Lived Electrophilic Metabolites of the Anticancer Agent Laromustine (VNP40101M)

    by A-E. F. Nassar, I. King, J. Du

    Laromustine (VNP40101M; 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino) carbonylhydrazine) is a novel sulfonylhydrazine alkylating agent. Phase 1 metabolism of laromustine was reported recently and showed that laromustine undergoes rearrangement, dehalogenation, and hydrolysis at physiological pH to form active moieties. (1) A mechanism for the rearrangement was proposed on the basis of fragmentation ions. (1), (2) In this article, we report the phase II conjugates of VNP40101M and VNP4090CE which were formed after incubation of VNP40101M or VNP4090CE with pooled human liver microsomes (HLM) and cofactors nicotinamide adenine dinucleotide phosphate (NADPH), glutathione (GSH), N-acetylecysteine (NAC), and cysteine (CYS). Eight novel phase II conjugates (M-1 to M-8) were identified and characterized by hydrogen−deuterium exchange (H-D), stable isotope (13C-labeled VNP40101M), and MSn experiments. M-4 and M-5 were further confirmed by nuclear magnetic resonance spectroscopy (NMR). The short-lived CH3SO2CH2CH2−, methylformamide and CH3SO2NHN═CHCH2− moieties were generated from VNP40101M. The reactive intermediates CH3SO2CH2CH2− and methylformamide formed conjugates with GSH, CYS, and NAC. The CH3SO2NHN═CHCH2− moiety formed conjugates with GSH and NAC. M-2, M-4, and M-6 were only detected from the incubation of VNP40101M because VNP4090CE does not contain a methylformamide group. All other conjugates were formed by both VNP40101M and VNP4090CE. The in vitro studies found that VNP40101M and VNP4090CE undergo activation in human liver microsomes. The results from this study showed that laromustine produces several reactive intermediates that may play a role in the toxicities seen in the clinical trials.


  • Open Access

    In Vitro Profiling and Mass Balance of the Anti-Cancer Agent Laromustine [14C]-VNP40101M by Rat, Dog, Monkey and Human Liver Microsomes

    by A-E. F. Nassar, J. Du, M. Belcourt, X. Lin, I. King

    In Vitro Profiling and Mass Balance of the Anti-Cancer Agent Laromustine [14C]-VNP40101M by Rat, Dog, Monkey and Human Liver Microsomes


  • An in Vitro Evaluation of the Victim and Perpetrator Potential of the Anticancer Agent Laromustine (VNP40101M), Based on Reaction Phenotyping and Inhibition and Induction of Cytochrome P450 Enzymes

    by Alaa-Eldin F. Nassar, Ivan King, Brandy L. Paris, Lois Haupt, Florence Ndikum-Moffor, Rebecca Campbell, Etsuko Usuki, Jennifer Skibbe, Dan Brobst, Brian W. Ogilvie, et al.

    Laromustine (VNP40101M, also known as Cloretazine) is a novel sulfonylhydrazine alkylating (anticancer) agent. Laromustine generates two types of reactive intermediates: 90CE and methylisocyanate. When incubated with rat, dog, monkey, and human liver microsomes, [14C]laromustine was converted to 90CE (C-8) and seven other radioactive components (C-1–C-7). There was little difference in the metabolite profile among the species examined, in part because the formation of most components (C-1–C-6 and 90CE) did not require NADPH but involved decomposition and/or hydrolysis. The exception was C-7, a hydroxylated metabolite, largely formed by CYP2B6 and CYP3A4/5. Laromustine caused direct inhibition of CYP2B6 and CYP3A4/5 (the two enzymes involved in C-7 formation) as well as of CYP2C19. Ki values were 125 μM for CYP2B6, 297 μM for CYP3A4/5, and 349 μM for CYP2C19 and were greater than the average clinical plasma Cmax of laromustine (25 μM). There was evidence of time-dependent inhibition of CYP1A2, CYP2B6, and CYP3A4/5. Treatment of primary cultures of human hepatocytes with up to 100 μM laromustine did not induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP3A4/5, but the highest concentration of laromustine decreased the activity and levels of immunoreactive CYP3A4. The results of this study suggest the laromustine has 1) negligible victim potential with respect to metabolism by cytochrome P450 enzymes, 2) negligible enzyme-inducing potential, and 3) the potential in some cases to cause inhibition of CYP2B6, CYP3A4, and possibly CYP2C19 during and shortly after the duration of intravenous administration of this anticancer drug, but the clinical effects of such interactions are likely to be insignificant.


  • Open Access

    Novel Approach to Performing Metabolite Identification in Drug Metabolism

    by A.- E. F. Nassar, D. Y. Lee

    A novel online method is developed, using liquid chromatography (LC)-accurate radioisotope counting dynamic-flow (ARC) coupled with a radioactivity detector and mass spectrometer, for metabolite identification in drug discovery and development. This method offers the advantages of improved sensitivity for detecting radiolabeled drugs as well as streamlining the process of identifying and characterizing metabolites. For the purposes of evaluating this method, in vitro human liver microsomal incubations with [14C]dextromethorphan are conducted. Online separation and identification of [14C]dextromethorphan metabolites are achieved without intensive sample preparation, concentration, or fraction collection. Mass spectrometric analysis identified and characterized the metabolites of dextromethorphan formed by N- and O-dealkylation, correlated well with previously published results. Chromatographic peaks for [14C]dextromethorphan and its metabolites are collected online, then infused for extended periods of time at a flow rate of 10 µL/min while maintaining the column pressure. The continuous analytical signal input allowed acquisition of a higher order of multistage fragmentation for both major and minor metabolites. The multistage MS fragmentation pattern obtained for the metabolites allowed defining the sites of metabolism for dextromethorphan. Further evaluations of this method are also conducted using a [14C]compound A to check the linearity and sensitivity of the dynamic-flow method. The R2 value is 0.996 for the dynamic-flow method between 50 and 600 disintegrations per minute (dpm); the limit of detection for LC-ARC is 20 dpm, which is approximately 10 times more sensitive than conventional continuous-flow radioactivity detection techniques. The overall results suggest that the combination of LC-ARC with radioactivity detection and mass spectrometry has great potential as a powerful tool for enhancing the sensitivity of radioisotope measurement in metabolite identification studies during drug discovery and development.


    • 1 January 2007
      • Vol. 10  (1) , 47-52

    Drug interactions: concerns and current approaches.

    by Alaa-Eldin F Nassar, Rasmy E Talaat, Hajime Tokuno

    Following the recent withdrawal of several prominent drugs from US and European markets because of detrimental drug-drug interactions, metabolic drug interactions have received considerable attention in the pharmaceutical industry. In turn, the question of drug safety has received significant legal, regulatory and commercial emphasis, bringing this issue to the forefront of both industry and government drug agendas. The value of predicting the drug interactions of compounds as early as possible in the drug discovery process for all therapeutic areas cannot be underestimated. From 1964 to 1999, approximately 8% of the drugs approved by the FDA were later withdrawn from the US market. Pharmaceutical companies are facing increasing pressure to prove the long-term safety of their products, and this is complicated by the fact that animal models are not perfectly predictive of human responses, and may provide contradictory information. The failure to address safety concerns successfully during the drug optimization process may result in companies withdrawing any approved drugs from the market; drug safety issues not only present human health consequences, but also have a negative economic and public relations impact on the pharmaceutical industry. This paper discusses the significance of drug interactions, and addresses strategies to evaluate the potential of a drug candidate for drug interactions.


    • 1 January 2006
      • Vol. 9  (1) , 61-74

    The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?

    by Alaa-Eldin F Nassar, Rasmy E Talaat, Amin M Kamel

    Absorption, distribution, metabolism, excretion and toxicology (ADMET) studies are widely used in drug discovery and development to help obtain the optimal balance of properties necessary to convert lead compounds into drugs that are safe and effective for human use. Drug discovery efforts have been aimed at identifying and addressing metabolism issues at the earliest possible stage, by developing and applying innovative liquid chromatography-mass spectrometry (LC-MS)-based techniques and instrumentation, which are both faster and more accurate than prior techniques. Such new approaches are demonstrating considerable potential to improve the overall safety profile of drug candidates throughout the drug discovery and development process. These emerging techniques streamline and accelerate the process by eliminating potentially harmful candidates earlier and improving the safety of new drugs. In the area of drug metabolism, for example, revolutionary changes have been achieved by the combination of LC-MS with innovative instrumentation such as triple quadrupoles, ion traps and time-of-flight mass spectrometry. In turn, most ADMET studies have come to rely on LC-MS for the analysis of an ever-increasing workload of potential candidates. This article provides a discussion on the importance of LC-MS in supporting drug metabolism studies, and highlights the relative merits of current applications for LC-MS in drug metabolism testing and analysis. These applications include in vitro and in vivo testing, pharmacokinetic profiling, chiral separations, stable isotope labeling, metabolic activation testing, metabolite characterization and radiolabeled-drug testing.